TinoMed (688806.SH) is a global-facing innovative biopharmaceutical company dedicated to developing alternative therapies for blood products. On July 21, 2026, TinoMed was listed on the STAR Market (Shanghai Stock Exchange's Sci-Tech Innovation Board). EFUNG Capital invested in TinoMed in 2023.